Loading...
FLAC logo

Frazier Lifesciences Acquisition CorporationNasdaqCM:FLAC Stock Report

Market Cap US$183.7m
Share Price
n/a
1Y5.7%
7D7.5%
1D4.9%
Portfolio Value
View

Frazier Lifesciences Acquisition Corporation

NasdaqCM:FLAC Stock Report

Market Cap: US$183.7m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Frazier Lifesciences Acquisition (FLAC) Stock Overview

Frazier Lifesciences Acquisition Corp. does not have significant operations. More details

FLAC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

FLAC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW495,210 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
495,210 investors already sharing narratives

Frazier Lifesciences Acquisition Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Frazier Lifesciences Acquisition
Historical stock prices
Current Share PriceUS$10.35
52 Week HighUS$32.88
52 Week LowUS$8.63
Beta0
1 Month Change3.40%
3 Month Change4.23%
1 Year Change5.72%
3 Year Changen/a
5 Year Changen/a
Change since IPO-4.17%

Recent News & Updates

Seeking Alpha Jul 19

Frazier Lifesciences SPAC said in talks to take NewAmsterdam Pharma public

SPAC Frazier Lifesciences Acquisition Corp. (NASDAQ:FLAC) is said in talks to take biotech company NewAmsterdam Pharma public. Frazier (FLAC) is in talks to with investors for a PIPE that would value the combined company at more than $700 million, according to a Bloomberg report.  NewAmsterdam, a biotech focused on treating metabolic diseases, announced in January 2021 that it completed a a $196 million Series A funding round. Investors in the round included Kaiser Foundation Hospital, Peter Thiel, Janus Henderson Investors and JVC Investment Partners. SPAC Frazier Lifesciences (FLAC) priced a $120 million IPO in December 2020. FLAC said at the time it intended to focus on the biotechnology sector in developed countries including, but not limited to, the United States and countries in Europe.

Recent updates

Seeking Alpha Jul 19

Frazier Lifesciences SPAC said in talks to take NewAmsterdam Pharma public

SPAC Frazier Lifesciences Acquisition Corp. (NASDAQ:FLAC) is said in talks to take biotech company NewAmsterdam Pharma public. Frazier (FLAC) is in talks to with investors for a PIPE that would value the combined company at more than $700 million, according to a Bloomberg report.  NewAmsterdam, a biotech focused on treating metabolic diseases, announced in January 2021 that it completed a a $196 million Series A funding round. Investors in the round included Kaiser Foundation Hospital, Peter Thiel, Janus Henderson Investors and JVC Investment Partners. SPAC Frazier Lifesciences (FLAC) priced a $120 million IPO in December 2020. FLAC said at the time it intended to focus on the biotechnology sector in developed countries including, but not limited to, the United States and countries in Europe.

Shareholder Returns

FLACUS Capital MarketsUS Market
7D7.5%-0.4%-0.9%
1Y5.7%2.5%19.4%

Return vs Industry: FLAC exceeded the US Capital Markets industry which returned -21.3% over the past year.

Return vs Market: FLAC exceeded the US Market which returned -20.4% over the past year.

Price Volatility

Is FLAC's price volatile compared to industry and market?
FLAC volatility
FLAC Average Weekly Movement3.7%
Capital Markets Industry Average Movement3.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: FLAC has not had significant price volatility in the past 3 months.

Volatility Over Time: FLAC's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2020n/aJamie Topperwww.frazierlifesciencesacquisition.com

Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.

Frazier Lifesciences Acquisition Corporation Fundamentals Summary

How do Frazier Lifesciences Acquisition's earnings and revenue compare to its market cap?
FLAC fundamental statistics
Market capUS$183.72m
Earnings (TTM)-US$3.64m
Revenue (TTM)n/a
0.0x
P/S Ratio
-50.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FLAC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$3.64m
Earnings-US$3.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did FLAC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/24 05:40
End of Day Share Price 2022/11/23 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Frazier Lifesciences Acquisition Corporation is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.